V. Lucini

1.1k total citations
19 papers, 871 citations indexed

About

V. Lucini is a scholar working on Cellular and Molecular Neuroscience, Neurology and Psychiatry and Mental health. According to data from OpenAlex, V. Lucini has authored 19 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cellular and Molecular Neuroscience, 6 papers in Neurology and 4 papers in Psychiatry and Mental health. Recurrent topics in V. Lucini's work include Neurotransmitter Receptor Influence on Behavior (6 papers), Parkinson's Disease Mechanisms and Treatments (6 papers) and Neurological disorders and treatments (3 papers). V. Lucini is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (6 papers), Parkinson's Disease Mechanisms and Treatments (6 papers) and Neurological disorders and treatments (3 papers). V. Lucini collaborates with scholars based in Italy, India and United Kingdom. V. Lucini's co-authors include Fabrizio Stocchi, R. Giuliani, Mohit Bhatt, Rupam Borgohain, A. Lucca, József Attila Szász, Paolo Stanzione, Chandrashekhar Meshram, Patricia Rice and R. Anand and has published in prestigious journals such as European Respiratory Journal, Journal of Affective Disorders and Life Sciences.

In The Last Decade

V. Lucini

18 papers receiving 847 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V. Lucini Italy 12 511 268 157 116 106 19 871
AJ Lees United Kingdom 8 636 1.2× 272 1.0× 58 0.4× 81 0.7× 119 1.1× 19 885
Daniele Bravi Italy 22 649 1.3× 485 1.8× 144 0.9× 387 3.3× 144 1.4× 38 1.5k
Diana Paleacu Israel 17 672 1.3× 272 1.0× 143 0.9× 356 3.1× 150 1.4× 26 1.2k
Elizabeth F. Marshall United Kingdom 13 240 0.5× 431 1.6× 181 1.2× 223 1.9× 112 1.1× 25 981
Elaine Perry United Kingdom 6 225 0.4× 277 1.0× 252 1.6× 274 2.4× 272 2.6× 10 1.0k
Teresa Morera‐Herreras Spain 15 300 0.6× 489 1.8× 110 0.7× 37 0.3× 216 2.0× 34 851
William H. Church United States 14 164 0.3× 593 2.2× 107 0.7× 64 0.6× 113 1.1× 22 1.1k
Maddalena Miele Italy 21 161 0.3× 568 2.1× 84 0.5× 68 0.6× 60 0.6× 59 1.3k
T N Chase United States 15 347 0.7× 402 1.5× 65 0.4× 198 1.7× 136 1.3× 20 853
Alexander Nies United States 14 91 0.2× 218 0.8× 156 1.0× 228 2.0× 53 0.5× 23 739

Countries citing papers authored by V. Lucini

Since Specialization
Citations

This map shows the geographic impact of V. Lucini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Lucini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Lucini more than expected).

Fields of papers citing papers by V. Lucini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Lucini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Lucini. The network helps show where V. Lucini may publish in the future.

Co-authorship network of co-authors of V. Lucini

This figure shows the co-authorship network connecting the top 25 collaborators of V. Lucini. A scholar is included among the top collaborators of V. Lucini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Lucini. V. Lucini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Anand, R., Richard D. Hartman, V. Lucini, et al.. (2015). Long-term efficacy of safinamide as add-on to levodopa in Parkinson’s disease fluctuating patients: results from a 2-year placebo-controlled trial. Journal of the Neurological Sciences. 357. e276–e276.
2.
Ponzoni, Luisa, Milena Moretti, Mariaelvina Sala, et al.. (2015). Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice. European Neuropsychopharmacology. 25(10). 1775–1786. 79 indexed citations
3.
Borgohain, Rupam, József Attila Szász, Paolo Stanzione, et al.. (2014). Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease. Movement Disorders. 29(10). 1273–1280. 177 indexed citations
4.
Barone, Paolo, et al.. (2013). Safinamide is effective as add-on treatment in both early and Advanced PD. Journal of the Neurological Sciences. 333. e69–e69. 2 indexed citations
5.
Borgohain, Rupam, József Attila Szász, Paolo Stanzione, et al.. (2013). Randomized trial of safinamide add‐on to levodopa in Parkinson's disease with motor fluctuations. Movement Disorders. 29(2). 229–237. 213 indexed citations
6.
Schapira, Anthony H.V., Fabrizio Stocchi, Marco Onofrj, et al.. (2012). Long‐term efficacy and safety of safinamide as add‐on therapy in early Parkinson's disease. European Journal of Neurology. 20(2). 271–280. 71 indexed citations
7.
Stocchi, Fabrizio, Rupam Borgohain, Marco Onofrj, et al.. (2011). A randomized, double‐blind, placebo‐controlled trial of safinamide as add‐on therapy in early Parkinson's disease patients. Movement Disorders. 27(1). 106–112. 96 indexed citations
8.
Szász, József Attila, et al.. (2011). 2.266 TWO-YEAR, PLACEBO-CONTROLLED SAFETY AND TOLERABILITY DATA FOR SAFINAMIDE AS ADD-ON TO LEVODOPA IN PATIENTS WITH PARKINSON'S DISEASE (PD). Parkinsonism & Related Disorders. 18. S132–S132. 2 indexed citations
9.
10.
Scaglione, Francesco, Silvano Esposito, Sara Leone, et al.. (2009). Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. European Respiratory Journal. 34(2). 394–400. 55 indexed citations
11.
Szász, József Attila, et al.. (2009). P2.108 Improvements in symptom severity and daily living with saflnamide in Parkinson's disease: a phase III, randomized, double-blind, placebo-controlled study. Parkinsonism & Related Disorders. 15. S118–S118. 1 indexed citations
12.
13.
Bellodi, Laura, et al.. (1997). Plasma tryptophan levels and tryptophan/neutral amino acid ratios in obsessive-compulsive patients with and without depression. Psychiatry Research. 69(1). 9–15. 14 indexed citations
14.
Moja, Egidio A., V. Lucini, Francesco Benedetti, & A. Lucca. (1996). Decrease in plasma phenylalanine and tyrosine after phenylalanine-tyrosine free amino acid solutions in man. Life Sciences. 58(26). 2389–2395. 51 indexed citations
15.
Lucini, V., A. Lucca, Marco Catalano, & Enrico Smeraldi. (1996). Predictive value of tryptophan/large neutral amino acids ratio to antidepressant response. Journal of Affective Disorders. 36(3-4). 129–133. 13 indexed citations
16.
Lucca, A., et al.. (1995). Neutral amino acid availability in two major psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 19(4). 615–626. 12 indexed citations
17.
Lucca, A., V. Lucini, Marco Catalano, Massimo Alfano, & Enrico Smeraldi. (1994). Plasma Tryptophan to Large Neutral Amino Acids Ratio and Therapeutic Response to a Selective Serotonin Uptake Inhibitor. Neuropsychobiology. 29(3). 108–111. 44 indexed citations
18.
Lucca, A., et al.. (1993). Serine and glycine metabolism in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 17(6). 947–953. 6 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by AJ Lees Breakdown of academic impact, for papers by Daniele Bravi Breakdown of academic impact, for papers by Diana Paleacu Breakdown of academic impact, for papers by Elizabeth F. Marshall Breakdown of academic impact, for papers by Elaine Perry Breakdown of academic impact, for papers by Teresa Morera‐Herreras Breakdown of academic impact, for papers by William H. Church Breakdown of academic impact, for papers by Maddalena Miele Breakdown of academic impact, for papers by T N Chase Breakdown of academic impact, for papers by Alexander Nies
Rankless by CCL
2026